Nanopores can activate human T cells without biochemical signals

Tertiary lymphoid structures (TLS) have been identified as harboring stem-like tumour-specific T cells, according to new research published in Nature. This discovery could significantly impact the understanding and treatment of cancers such as melanoma, renal cell carcinoma, and head and neck cancer. The study, conducted using single-cell RNA sequencing (scRNA-seq), single-cell T cell receptor (scTCR-seq), and bulk RNA-seq technologies, revealed that these structures contain a unique population of T cells with characteristics similar to stem cells. These findings suggest that TLS might play a crucial role in generating long-term immunity against tumours. The research was carried out over several years, involving two cohorts of patients. Cohort one included individuals with melanoma, while cohort two focused on patients diagnosed with renal cell carcinoma. Researchers collected biological samples from these patients and performed extensive genomic and transcriptomic analyses. The data were stored in public repositories such as the dbGaP portal and the Broad Single Cell Portal, allowing future studies to access and build upon the findings. The datasets include scRNA-seq and scTCR-seq data from cohort one, along with bulk RNA-seq data, and spatial RNA-seq and TCR-seq data from cohort two. Key contributors to the study include researchers from leading institutions specializing in oncology and immunology. Among them are Dr. Michael Hugaboom and Dr. Chloé Tutu, who led the analysis of T cell populations within TLS. Their work built upon earlier studies that highlighted the importance of TLS in the context of immune checkpoint therapy. For example, prior research by Dr. Caroline Sautès-Fridman and colleagues demonstrated how TLS can influence the effectiveness of immunotherapies. Additionally, Dr. Sylvie Khanal and her team explored the mechanisms behind TLS formation, emphasizing the interplay between inflammation and antigen presentation. The presence of stem-like T cells within TLS suggests that these structures might serve as sites of sustained immune activation. In particular, the study found that these T cells exhibit features of memory T cells, which are known to persist in the body and respond to recurring threats. This characteristic makes them potentially valuable targets for immunotherapy strategies aimed at enhancing antitumour immunity. Furthermore, the research indicated that certain subtypes of T cells, such as TCF1+ T cells, are more commonly found in TLS and are associated with better patient outcomes. The implications of these findings extend beyond basic science into clinical practice. By identifying markers specific to stem-like T cells within TLS, clinicians may develop more targeted approaches to assess immune status and tailor treatments accordingly. For instance, the presence of mature TLS has been linked to improved responses to immune checkpoint inhibitors, independent of PD-L1 expression levels. This aligns with previous observations made by Dr. Laurence Vanhersecke and his team, who noted that the maturation of TLS correlates with enhanced therapeutic outcomes in solid tumours. Researchers are currently working on validating these findings in larger patient cohorts and exploring potential biomarkers that could guide clinical decision-making. They are also investigating how factors such as corticosteroid use might affect TLS development, based on earlier studies showing that corticosteroids impair germinal center formation in lung cancer. As the field continues to evolve, the role of TLS in shaping immune responses will likely become even clearer, offering new avenues for improving cancer care.